New hope for tough blood cancers: experimental drug targets CD70
NCT ID NCT07173595
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an experimental drug called QLS2309 in about 186 adults with CD70-positive blood cancers that have returned or not responded to standard therapy. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug by injection, and the study is currently recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 186 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1\. Subjects voluntarily participated and signed a written informed consent form * Age ≥ 18 years, male or female * ECOG performance status of 0-2 * Expected life-expectancy ≥ 3 months * CD70+ relapsed/refractory hematologic malignancies * Adequate organ function prior to QLS2309 administration * Female patients with fertility must agree to the use of effective contraceptive methods during the study period and within 35 days of discontinuation of the trial drug. * Male patients whose sexual partners are women of childbearing age must agree to use condoms during the study period and within 35 days of discontinuation of the trial drug during sexual intercourse. Exclusion Criteria: * Prior treatment with CD70-related antibodies, antibody-conjugated drugs (ADCs) or cell therapy products * Symptomatic central nervous system (CNS) involvement, leptomeningeal metastasis or spinal cord compression caused by metastasis * An active autoimmune diseases or known history of ≥ grade 3 irAE due to prior immunotherapy * Known history of other active malignant tumor within 3 years * Known history of chemotherapy, biological therapy, endocrine therapy, immunotherapy, monoclonal antibodies, etc. within 4 weeks * Known history of active hepatitis B/C infection, HIV infection, Treponema pallidum infection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Relapsed or refractory hematologic malignancies are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.